Literature DB >> 23269439

The p.Ala510Val mutation in the SPG7 (paraplegin) gene is the most common mutation causing adult onset neurogenetic disease in patients of British ancestry.

Richard H Roxburgh1, Renate Marquis-Nicholson, Fern Ashton, Alice M George, Rod A Lea, David Eccles, Stuart Mossman, Thomas Bird, Koen L van Gassen, Erik-Jan Kamsteeg, Donald R Love.   

Abstract

The c.1529C >T change in the SPG7 gene, encoding the mutant p.Ala510Val paraplegin protein, was first described as a polymorphism in 1998. This was based on its frequency of 3 % and 4 % in two separate surveys of controls in the United Kingdom (UK) population. Subsequently, it has been found to co-segregate with disease in a number of different populations. Yeast expression studies support its having a deleterious effect. In this paper a consanguineous sibship is described in which four members who are homozygous for the p.Ala510Val variant present with a spectrum of disease. This spectrum encompasses moderately severe hereditary spastic paraparesis (HSP) with more minor ataxia in two siblings, moderately severe ataxia without spasticity in the third, and a very mild gait ataxia in the fourth. Two of the siblings also manifest vestibular failure. The remaining eight unaffected siblings are either heterozygous for the p.Ala510Val variant, or do not carry it at all. Homozygosity mapping using a high-density SNP array across the whole genome found just 11 genes (on two regions of chromosome 3) outside the SPG7 region on chromosome 16, which were homozygously shared by the affected siblings, but not shared by the unaffected siblings; none of them are likely to be causative. The weight of evidence is strongly in favour of the p.Ala510Val variant being a disease-causing mutation. We present additional data from the Auckland City Hospital neurogenetics clinic to show that the p.Ala510Val mutation is prevalent amongst HSP patients of UK extraction belying any suggestion that European p.Ala510Val haplotypes harbour a disease-causing mutation which the UK p.Ala510Val haplotypes do not. Taken together with previous findings of a carrier frequency of 3-4 % in the UK population (giving a homozygosity rate of 20-40/100,000), the data imply that the p.Ala510Val is the most common mutation causing neurogenetic disease in adults of UK ancestry, albeit the penetrance may be low or the disease caused may be mild.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269439     DOI: 10.1007/s00415-012-6792-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

Review 2.  Cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS): a review of the clinical features and video-oculographic diagnosis.

Authors:  David J Szmulewicz; John A Waterston; Hamish G MacDougall; Stuart Mossman; Andrew M Chancellor; Catriona A McLean; Saumil Merchant; Peter Patrikios; G Michael Halmagyi; Elsdon Storey
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

3.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

4.  Visual vestibular interaction in the dynamic visual acuity test during voluntary head rotation.

Authors:  M H Lee; S J Durnford; J S Crowley; A H Rupert
Journal:  Aviat Space Environ Med       Date:  1997-02

5.  Prevalence of multiple sclerosis in Rochdale.

Authors:  D I Shepherd; A Summers
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

6.  Amplicon-based high-throughput pooled sequencing identifies mutations in CYP7B1 and SPG7 in sporadic spastic paraplegia patients.

Authors:  N A Schlipf; R Schüle; S Klimpe; K N Karle; M Synofzik; J Schicks; O Riess; Ludger Schöls; P Bauer
Journal:  Clin Genet       Date:  2011-06-13       Impact factor: 4.438

7.  A clinical, genetic, and biochemical characterization of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia.

Authors:  Alessia Arnoldi; Alessandra Tonelli; Francesca Crippa; Gaetano Villani; Consiglia Pacelli; Manuela Sironi; Uberto Pozzoli; Maria Grazia D'Angelo; Giovanni Meola; Andrea Martinuzzi; Claudia Crimella; Francesca Redaelli; Chris Panzeri; Alessandra Renieri; Giacomo Pietro Comi; Anna Carla Turconi; Nereo Bresolin; Maria Teresa Bassi
Journal:  Hum Mutat       Date:  2008-04       Impact factor: 4.878

8.  SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V.

Authors:  E Sánchez-Ferrero; E Coto; C Beetz; J Gámez; A I Corao; M Díaz; J Esteban; E del Castillo; G Moris; J Infante; M Menéndez; S I Pascual-Pascual; A López de Munaín; M J Garcia-Barcina; V Alvarez
Journal:  Clin Genet       Date:  2012-05-21       Impact factor: 4.438

9.  A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia.

Authors:  Philip A Wilkinson; Andrew H Crosby; Christopher Turner; Lloyd J Bradley; Lionel Ginsberg; Nicholas W Wood; Anthony H Schapira; Thomas T Warner
Journal:  Brain       Date:  2004-02-25       Impact factor: 13.501

10.  Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease.

Authors:  G Casari; M De Fusco; S Ciarmatori; M Zeviani; M Mora; P Fernandez; G De Michele; A Filla; S Cocozza; R Marconi; A Dürr; B Fontaine; A Ballabio
Journal:  Cell       Date:  1998-06-12       Impact factor: 41.582

View more
  14 in total

Review 1.  Ophthalmic manifestations of inherited neurodegenerative disorders.

Authors:  Hannah M Kersten; Richard H Roxburgh; Helen V Danesh-Meyer
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

2.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.

Authors:  Laura M Amendola; Gail P Jarvik; Michael C Leo; Heather M McLaughlin; Yassmine Akkari; Michelle D Amaral; Jonathan S Berg; Sawona Biswas; Kevin M Bowling; Laura K Conlin; Greg M Cooper; Michael O Dorschner; Matthew C Dulik; Arezou A Ghazani; Rajarshi Ghosh; Robert C Green; Ragan Hart; Carrie Horton; Jennifer J Johnston; Matthew S Lebo; Aleksandar Milosavljevic; Jeffrey Ou; Christine M Pak; Ronak Y Patel; Sumit Punj; Carolyn Sue Richards; Joseph Salama; Natasha T Strande; Yaping Yang; Sharon E Plon; Leslie G Biesecker; Heidi L Rehm
Journal:  Am J Hum Genet       Date:  2016-05-12       Impact factor: 11.025

3.  SPG7 mutations explain a significant proportion of French Canadian spastic ataxia cases.

Authors:  Karine Choquet; Martine Tétreault; Sharon Yang; Roberta La Piana; Marie-Josée Dicaire; Megan R Vanstone; Jean Mathieu; Jean-Pierre Bouchard; Marie-France Rioux; Guy A Rouleau; Kym M Boycott; Jacek Majewski; Bernard Brais
Journal:  Eur J Hum Genet       Date:  2015-12-02       Impact factor: 4.246

Review 4.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

Review 5.  Clinical application of next-generation sequencing to the practice of neurology.

Authors:  Jessica Rexach; Hane Lee; Julian A Martinez-Agosto; Andrea H Németh; Brent L Fogel
Journal:  Lancet Neurol       Date:  2019-05       Impact factor: 44.182

6.  Loss of paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with SPG7.

Authors:  Giulia Coarelli; Rebecca Schule; Bart P C van de Warrenburg; Peter De Jonghe; Claire Ewenczyk; Andrea Martinuzzi; Matthis Synofzik; Elisa G Hamer; Jonathan Baets; Mathieu Anheim; Ludger Schöls; Tine Deconinck; Pegah Masrori; Bertrand Fontaine; Thomas Klockgether; Maria Grazia D'Angelo; Marie-Lorraine Monin; Jan De Bleecker; Isabelle Migeotte; Perrine Charles; Maria Teresa Bassi; Thomas Klopstock; Fanny Mochel; Elisabeth Ollagnon-Roman; Marc D'Hooghe; Christoph Kamm; Delia Kurzwelly; Melanie Papin; Claire-Sophie Davoine; Guillaume Banneau; Sophie Tezenas du Montcel; Danielle Seilhean; Alexis Brice; Charles Duyckaerts; Giovanni Stevanin; Alexandra Durr
Journal:  Neurology       Date:  2019-05-08       Impact factor: 9.910

7.  Novel genotype-phenotype and MRI correlations in a large cohort of patients with SPG7 mutations.

Authors:  Channa A Hewamadduma; Nigel Hoggard; Ronan O'Malley; Megan K Robinson; Nick J Beauchamp; Ruta Segamogaite; Jo Martindale; Tobias Rodgers; Ganesh Rao; Ptolemaios Sarrigiannis; Priya Shanmugarajah; Panagiotis Zis; Basil Sharrack; Christopher J McDermott; Pamela J Shaw; Marios Hadjivassiliou
Journal:  Neurol Genet       Date:  2018-10-24

8.  Phenotypic and molecular analyses of primary lateral sclerosis.

Authors:  Hiroshi Mitsumoto; Peter L Nagy; Chris Gennings; Jennifer Murphy; Howard Andrews; Raymond Goetz; Mary Kay Floeter; Jonathan Hupf; Jessica Singleton; Richard J Barohn; Sharon Nations; Christen Shoesmith; Edward Kasarskis; Pam Factor-Litvak
Journal:  Neurol Genet       Date:  2015-04-14

9.  Burden of Rare Variants in ALS and Axonal Hereditary Neuropathy Genes Influence Survival in ALS: Insights from a Next Generation Sequencing Study of an Italian ALS Cohort.

Authors:  Stefania Scarlino; Teuta Domi; Laura Pozzi; Alessandro Romano; Giovanni Battista Pipitone; Yuri Matteo Falzone; Lorena Mosca; Silvana Penco; Christian Lunetta; Valeria Sansone; Lucio Tremolizzo; Raffaella Fazio; Federica Agosta; Massimo Filippi; Paola Carrera; Nilo Riva; Angelo Quattrini
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

10.  Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Authors:  Xiaoming Jia; Lohith Madireddy; Stacy Caillier; Adam Santaniello; Federica Esposito; Giancarlo Comi; Olaf Stuve; Yuan Zhou; Bruce Taylor; Trevor Kilpatrick; Filippo Martinelli-Boneschi; Bruce A C Cree; Jorge R Oksenberg; Stephen L Hauser; Sergio E Baranzini
Journal:  Ann Neurol       Date:  2018-07-03       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.